Scarica l'app Stockscreener
0.3709
8.22%
-0.0332
Dopo l'orario di chiusura:
.38
0.0091
+2.45%
Precedente Chiudi:
$0.4041
Aprire:
$0.3987
Volume 24 ore:
2.67M
Relative Volume:
3.70
Capitalizzazione di mercato:
$1.13M
Reddito:
-
Utile/perdita netta:
$-23.66M
Rapporto P/E:
-0.0268
EPS:
-13.84
Flusso di cassa netto:
$-10.14M
1 W Prestazione:
+3.03%
1M Prestazione:
-3.16%
6M Prestazione:
-76.07%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.3614
$0.42
Intervallo di 1 settimana:
$0.3379
$0.444
Portata 52W:
$0.325
$2.16
Tnf Pharmaceuticals Inc Stock (TNFA) Company Profile
Nome
Tnf Pharmaceuticals Inc
Settore
Industria
Telefono
856-848-8698
Indirizzo
855 N. WOLFE STREET, BALTIMORE
Confronta TNFA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNFA
Tnf Pharmaceuticals Inc
|
0.3709 | 1.13M | 0 | -23.66M | -10.14M | -13.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tnf Pharmaceuticals Inc Borsa (TNFA) Ultime notizie
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
A Key Driver Transforming the TNF Alpha Inhibitors Market in 2025: The Prevalence Of Inflammatory Diseases ... - WhaTech
Contrasting Myriad Genetics (NASDAQ:MYGN) & TNF Pharmaceuticals (NASDAQ:TNFA) - Defense World
TNF Pharmaceuticals faces Nasdaq delisting over price - Investing.com
TNF Pharmaceuticals faces Nasdaq delisting over price By Investing.com - Investing.com South Africa
Akers’ Proposed Merger Partner MyMD Pharmaceuticals Announces Issuance of Key Patent - Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Sarcopenia Market Expected to Experience Major Growth by 2034, - openPR.com
TNF Pharmaceuticals presents isomyosamine data - Yahoo Finance
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia - Joplin Globe
Breakthrough Oral Treatment for Muscle Loss: TNF Pharma Reports Positive Clinical Data - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
TNFA stock touches 52-week low at $0.34 amid market challenges - Investing.com UK
TNF Pharmaceuticals Discusses Isomyosamine Progress in Call - TipRanks
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 - BioSpace
Raythera describes new TNF-α modulators - BioWorld Online
RILY’s current quarter earnings: What analysts forecast? - US Post News
LGVN To Complete ELPIS II Enrollment By Q2, Time To Keep An Eye On NXGL, What's The Buzz At ACON? - RTTNews
Are T1 Energy Inc (FREY) shares a good deal now? - US Post News
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor - BioSpace
Can This First-Ever Oral TNF Inhibitor Disrupt a $40 Billion Market? Phase 2b Trial Begins - StockTitan
TNFA stock touches 52-week low at $0.43 amid market challenges - Investing.com Australia
Sarcopenia Market Share Projected to Climb to USD 4.23 Billion by 2030 - Industry Today
TNFA stock touches 52-week low at $0.48 amid market challenges - MSN
TNFA stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa
Teva- Pharmaceutical Industries Ltd. ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
FHN’s Stock Market Expedition: Traversing Gains and Losses in 2023 - The InvestChronicle
Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), in the United States of America - BioSpace
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Post-Trade Analysis: Avinger Inc (AVGR) Slides -30.15, Closing at 0.39 - The Dwinnex
Daily Market Movement: Lottery.com Inc (LTRY) Sees a 187.81 Increase, Closing at 1.41 - The Dwinnex
In the Green: TNF Pharmaceuticals Inc (TNFA) Closes at 0.60, Up/Down 6.96 from Previous Day - The Dwinnex
TNFA stock touches 52-week low at $1.02 amid market challenges - MSN
TNFA stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
TNF Pharmaceuticals to study TNF-alpha in patients taking GLP-1s - TipRanks
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment - Marketscreener.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
InMed's Alzheimer's Drug Shows Breakthrough Results in Reducing Brain Inflammation - Stock Titan
Coeptis Therapeutics (Nasdaq: COEP) Emerges as a Biopharma Innovator Leveraging AI-Driven Marketing - The Globe and Mail
TNF Pharmaceuticals to expand clinical trials for isomyosamine - Investing.com
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion - Business Wire
Shattuck Labs CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs - Business Wire
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Inflammatory Bowel Disease Treatment Market Report 2024, Share And Growth - WhaTech
TNF Alpha Inhibitors Market Overview 2024-2033 – Share, Trends, Demand, Outlook - WhaTech
Premarket Action Is Heating Up For This Biotech - MSN
Tnf Pharmaceuticals Inc Azioni (TNFA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):